


AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Previously Presented) A compound of the general formula (I):



wherein

A is a heteroalkyl-, heterocycloalkyl-, heteroalkyl-cycloalkyl-, heteroaryl- or heteroarylalkyl group,

G-E is selected from the following groups,



or is part of an optionally substituted cyclopropyl ring,

n is 0, 1 or 2,





R¹ is a C₁-C₄ alkyl- or a C₃-C₄-cycloalkyl group,

X is oxygen or a group of the formula NR², wherein R² is hydrogen, OH, NH₂, NH(Alkyl), N(alkyl)₂, a alkyl-, alkenyl-, alkynyl-, hetero-alkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcyclo-alkyl-, heteroalkylcycloalkyl-, heterocycloalkyl-, aralkyl- or a heteroaralkyl group,

R³ and R⁴ are independently of each other hydrogen, a C₁-C₄ alkyl group or together are part of a cycloalkyl group with 3 or 4 ring atoms,

or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof.

2. (Previously Presented) A compound according to claim 1, wherein A is a group of the formula $-\text{C}(\text{CH}_3)=\text{CHR}^5$, $-\text{C}(\text{C}_2\text{H}_5)=\text{CHR}^5$, $-\text{C}(\text{Cl})=\text{CHR}^5$ or $-\text{CH}=\text{CHR}^5$, wherein R^5 is a heteroaryl- or a heteroarylalkyl group.
3. (Previously Presented) A compound according to claim 1, wherein A is a group of the general formula (II), (III), (IV), or (V):



wherein

Q is sulphur, oxygen or a group of the formula NR^7 , wherein R^7 is hydrogen, a $\text{C}_1\text{-C}_4$ alkyl group or a $\text{C}_1\text{-C}_4$ -heteroalkyl group, z is nitrogen or a CH group and R^6 is a group of the formula OR^8 or NHR^8 , an alkyl-, alkenyl, alkynyl- or a heteroalkyl group, wherein R^8 is hydrogen, a $\text{C}_1\text{-C}_4$ -alkyl group or a $\text{C}_1\text{-C}_4$ -heteroalkyl group.

4. (Previously Presented) A compound according to claim 3, wherein z is a CH-group.
5. (Previously Presented) A compound according to claim 3, wherein Q is sulphur or oxygen.
6. (Previously Presented) A compound according to claim 3, wherein R^6 is a group of the formula CH_3 , CH_2OH or CH_2NH_2 .
7. (Previously Presented) A compound according to claim 1, wherein X is oxygen.

8. (Previously Presented) A compound according to claim 1, wherein R¹ is a methyl group.
9. (Previously Presented) A compound according to claim 1, wherein R³ and R⁴ are methyl groups.
10. (Currently Amended) A method of synthesizing the compound of claim 1 comprising ~~the use of (a) coupling (i) (1,1-Dialkyl-2-oxo-butylsulfanyl)-acetic acid or its derivatives as an intermediate, wherein the derivatives are a derivative thereof~~ selected from the group consisting of sulfoxides, sulfones, esters, amides, 3-haloderivates, (3-bromo-1,1-dimethyl-2-oxo-butylsulfanyl)-acetic acid esters of methanol and ethanol, and sulfoxides of methanol and ethanol to (ii) a compound selected from the group consisting of (1E,5Z,3S,10S)-11-(tert-butyl-dimethylsilyloxy)-2,6,10-trimethyl-1-(2-methyl-thiazol-4-yl)-undeca-1,5-dien-3-ol, (1E,5Z,3S,10S)-11-(tert-butyl-dimethyl-silyloxy)-2,6,10-trimethyl-1-(2-methyloxazol-4-yl)-undeca-1,5-dien-3-ol, and (1E,5Z,3S,10S)-11-(tert-butyl-dimethyl-silyloxy)-2,6,10-trimethyl-1-(2-methyl-pyridine-2-yl)-undeca-1,5,9-trien-3-ol via an esterification reaction, and (b) subjecting the product of step (a) to an aldol condensation reaction, to synthesize the compound of claim 1.
11. (Previously Presented) A pharmaceutical composition containing a compound according to claim 1 and optionally a carrier and/or adjuvants.
12. (Previously Presented) A method of treating cancer in a human comprising administering the compound of claim 1 to the human.
13. (Previously Presented) A method of treating cancer in a human comprising administering the pharmaceutical composition of claim 11 to the human.